The NA Health and Welfare Committee decided that reimbursement for AstraZeneca's lung cancer drug ‘Tagrisso (osimertinib)’ in the first line is necessary and requested its prompt reimbursement listing to the government.

Min-soo Park, the 2nd vice minister of the Ministry of Health and Welfare, and the Health Insurance Review and Assessment Service also agreed to the National Assembly's decision and promised to promptly go through the reimbursement procedure.

On the 18th, the Health and Welfare Committee's Petition Review Subcommittee (Chair Young-Hee Choi) reviewed the petition which requested reimbursement of the lung cancer drug Tagrisso as a first-line treatment.

The